Therapeutic targeting of oncogenic K-Ras by a covalent catalytic site inhibitor - Wikidata - awgldk - TriplyDB

Therapeutic targeting of oncogenic K-Ras by a covalent catalytic site inhibitor

Therapeutic targeting of oncogenic K-Ras by a covalent catalytic site inhibitor

http://www.wikidata.org/entity/Q41915120

about

The value of genomics in dissecting the RAS-network and in guiding therapeutics for RAS-driven cancers KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective Treatment K-Ras protein as a drug target Prodrugs of phosphonates and phosphates: crossing the membrane barrier KRAS as a Therapeutic Target In situ selectivity profiling and crystal structure of SML-8-73-1, an active site inhibitor of oncogenic K-Ras G12C Selective Inhibition of the Immunoproteasome by Structure-Based Targeting of a Non-catalytic Cysteine ARF6 Is an Actionable Node that Orchestrates Oncogenic GNAQ Signaling in Uveal Melanoma A Pan-GTPase Inhibitor as a Molecular Probe Proteome-wide covalent ligand discovery in native biological systems Rationale for RAS mutation-tailored therapies.Targeting Non-Catalytic Cysteine Residues Through Structure-Guided Drug Discovery Targeting pathways downstream of KRAS in lung adenocarcinoma.Intrinsic K-Ras dynamics: A novel molecular dynamics data analysis method shows causality between residue pair motions The DPC4/SMAD4 genetic status determines recurrence patterns and treatment outcomes in resected pancreatic ductal adenocarcinoma: A prospective cohort study.Antibody targeting intracellular oncogenic Ras mutants exerts anti-tumour effects after systemic administration.Direct Ras Inhibitors Identified from a Structurally Rigidified Bicyclic Peptide Library.Upregulation of IGF1R by mutant RAS in leukemia and potentiation of RAS signaling inhibitors by small-molecule inhibition of IGF1R Direct inhibition of oncogenic KRAS by hydrocarbon-stapled SOS1 helices Molecularly targeted therapies in non-small-cell lung cancer annual update 2014 Drugging the undruggable RAS: Mission possible?Small-molecule modulation of Ras signaling.Mutant KRAS as a critical determinant of the therapeutic response of colorectal cancer.Stimulus-dependent differences in signalling regulate epithelial-mesenchymal plasticity and change the effects of drugs in breast cancer cell lines.Inhibition of Ras signaling by blocking Ras-effector interactions with cyclic peptides Functional signaling pathway analysis of lung adenocarcinomas identifies novel therapeutic targets for KRAS mutant tumors.Covalent targeting of acquired cysteines in cancer Discovery of a Direct Ras Inhibitor by Screening a Combinatorial Library of Cell-Permeable Bicyclic Peptides.8-Hydroxyquinoline-based inhibitors of the Rce1 protease disrupt Ras membrane localization in human cells.Allosteric inhibition of antiapoptotic MCL-1.Inhibition of prenylated KRAS in a lipid environment Identification of Wee1 as a novel therapeutic target for mutant RAS-driven acute leukemia and other malignancies.Searching for the Chokehold of NRAS Mutant Melanoma.How to Target Activated Ras Proteins: Direct Inhibition vs. Induced Mislocalization.Therapeutic Approaches to RAS Mutation.KRAS - An Evolving Cancer Target Inhibition of RAS function through targeting an allosteric regulatory site.Prediction of the repeat domain structures and impact of parkinsonism-associated variations on structure and function of all functional domains of leucine-rich repeat kinase 2 (LRRK2).Growth factor transduction pathways: paradigm of anti-neoplastic targeted therapy.Non-small-cell lung cancers: a heterogeneous set of diseases.

P2860

Q26747403-E0187279-A7F0-447B-93C0-040866E38FAF Q26751520-B92F5C4E-0FC4-4240-A1B4-1444313832FB Q26766684-3B3BD2A9-1843-4685-B0E6-6EC82DB1C304 Q27005712-A8BAA911-9177-4AE6-8741-DC6F4CF95D8D Q27007866-948B57C7-669E-4943-911C-B1A8A710C66C Q27684047-C52873B9-6A79-457B-9968-122608DBA7EE Q27702605-C1E6CDC6-9AE7-40F9-9B39-EF381279FAF6 Q28115305-467928D6-C5E5-4D4A-8415-638CF504895E Q28547072-695FFCB5-3328-4DD3-A43A-39678F0B6A4E Q28829116-38494E18-3B76-4AD7-9A94-F6B53AC16A65 Q30244673-DCA8B332-189A-4A4A-A5F5-38ECE41148BD Q30390894-22CBEDAE-923F-43E6-8037-3C5E3C16AC33 Q30597330-3BD0B1DC-27DA-4932-AE88-527A0C9B4923 Q31142381-CE4CAFB8-F9C3-46A0-A646-AB292EFBC558 Q33566753-EF31D266-B5C2-4EBC-B575-246491CA83C1 Q33701979-38435955-5D5B-40E0-8298-C5208CADBAA4 Q34271187-57D90DD9-6A31-4953-BBC6-479BD8B7DC71 Q34438500-BAF15850-9E83-4FBE-84B0-C6C41B693C2F Q35089991-08B2EDBA-075B-4338-81BC-118BFA1B5C11 Q35136424-D5F2C7FA-8558-44DB-9D9C-91DC4DD997F1 Q35163434-C3B9DE8F-9FFE-4F02-A613-ABDC42490CF1 Q35188280-7AB7424A-DAFC-442A-B428-99CFA38A373C Q35213124-800F4EC8-F6A7-4CA6-A71C-553091593DE5 Q35610049-3DA6C0F2-2841-4221-A52A-DB2F600B8D39 Q35624144-A0EAC3E1-A825-4681-898F-19BCA97FBFB6 Q35808124-0902E3DA-B66D-4A09-A98A-694B769507C9 Q35858612-EFE5A64D-6653-4295-AEAD-08666E400008 Q35863269-C9AB0F7F-2DF4-4A7D-BB15-94EE91A397A8 Q35878817-FB57E3E1-8593-4D51-BCC2-BA66537C8B41 Q36012325-61CCB59B-C353-4D2C-BC47-8A9697856F8C Q36338169-B00EDAB9-9F87-4DCD-97FA-87609E1DF298 Q36341628-E4B73FD2-EEDB-4504-B9AB-EAF0F4CC0E63 Q37038604-812B4591-35B7-4EC5-BD17-21BF021162FD Q37113976-9312E8A8-FCDF-4711-9D81-3A4603DE8E1B Q37122874-AD96CBB4-292D-44C2-A3D7-AC036F1517C8 Q37261936-2C1CB4B0-14F6-45D9-AD48-E80A4117FF70 Q37540897-D347D890-4B4B-4F66-93AE-BD0B7B4BBA4A Q38182492-CA1FDA25-85AB-46E2-8376-388A3540B677 Q38218298-469B2F2F-22E6-4733-90EF-4965C77380B8 Q38233321-38AD9C87-846E-487E-BFF0-0788C1551530

P2860

Therapeutic targeting of oncogenic K-Ras by a covalent catalytic site inhibitor

http://www.wikidata.org/entity/Q41915120

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Therapeutic targeting of oncogenic K-Ras by a covalent catalytic site inhibitor

@en

type

label

Therapeutic targeting of oncogenic K-Ras by a covalent catalytic site inhibitor

@en

prefLabel

Therapeutic targeting of oncogenic K-Ras by a covalent catalytic site inhibitor

@en

P1433

Q41915120-A52EEEAC-AB21-4843-8B2B-FC5924E7EA8D

P1476

Q41915120-393515F3-1C2A-4EB4-ADD8-5A5C7FEF87BA

P2093

Q41915120-0ABEFD9A-2820-4A39-AA9C-474C2A8EE302

Q41915120-0DD19191-A727-49B6-9044-BC8C2B1F7415

Q41915120-327784F2-EB9D-4FAF-BD2E-06F182BDF308

Q41915120-6C0D5AA2-3EFD-4EEB-97A8-FAABEEBCD9C1

Q41915120-7551427B-822A-4644-BE7C-E10D9D90F66A

Q41915120-78F84E7B-3557-4DFA-A42F-5C67B3352353

Q41915120-B2EC5448-7C89-4581-A896-9D76A505356C

Q41915120-C4485F18-7141-46E9-ADCB-55B401B03493

Q41915120-C61B2A7C-24AD-4B7F-A01F-226972EBF3BE

Q41915120-CD063094-B551-44DC-99E9-CCD9AFA24FCC

P2860

Q41915120-079261BC-F2A3-4189-88DE-097D760488CF

Q41915120-079FB475-F981-4CA4-9DF6-F3CB423E137B

Q41915120-1102F6DB-8975-4CE6-B0A9-81D77D3FA57A

Q41915120-1120496B-5D3C-4C1A-AA4C-DE648CC4CE0B

Q41915120-141D85CD-02D0-4698-ADBC-46F58B098461

Q41915120-1616D2B9-2A91-4C15-909D-45C429AAF5E9

Q41915120-1D8A83C6-EEBF-46FF-9312-5396A13487F1

Q41915120-38010F87-FA1E-4AF4-BA86-4116CBDB6707

Q41915120-4CC793F3-C83A-4119-BF2D-DD5BD160B14C

Q41915120-58BA4C2F-AAB9-43BF-9FF9-EDC91C714702

P304

Q41915120-57820EF4-BD51-4861-AC76-A1D17C6890F5

P31

Q41915120-7193D388-D5A0-48A6-9EC2-BB7FD76006FB

P356

Q41915120-CA0C3176-6CE2-4B7C-BCD8-69D229643F0F

P407

Q41915120-13D26FAF-AE16-4632-95FC-A2784634827B

P433

Q41915120-5473BFEC-659C-4E4B-831B-AAA40A794BD8

P478

Q41915120-5379C466-E696-459A-B17F-24C1CCD2AEF5

P50

Q41915120-620A7560-4C71-4622-A9E0-A39DCBB25562

Q41915120-CBAA1325-FD5B-4761-96E2-6FE36097FA27

Q41915120-F07780CD-A798-45E7-92BF-2BB8CA44B468

P577

Q41915120-2C365582-420D-4A3B-BF4B-C06D7CF9080E

P5875

Q41915120-742A6B18-E124-450A-A937-63E925F8EEC0

P698

Q41915120-B64CBBB8-DB36-47F2-A726-F7B0FF642385

P932

Q41915120-89107709-4E00-46D6-A364-E8CCBF44FC85

P356

P1433

Angewandte Chemie International Edition

P1476

Therapeutic targeting of oncogenic K-Ras by a covalent catalytic site inhibitor

@en

P2093

Hwan Geun Choi

http://www.w3.org/2001/XMLSchema#string

Jarrod A Marto

http://www.w3.org/2001/XMLSchema#string

John Hunter

http://www.w3.org/2001/XMLSchema#string

Kenneth D Westover

http://www.w3.org/2001/XMLSchema#string

Martin Carrasco

http://www.w3.org/2001/XMLSchema#string

Michael E Pacold

http://www.w3.org/2001/XMLSchema#string

Nam Doo Kim

http://www.w3.org/2001/XMLSchema#string

Nathanael S Gray

http://www.w3.org/2001/XMLSchema#string

Rane A Harrison

http://www.w3.org/2001/XMLSchema#string

Sang Min Lim

http://www.w3.org/2001/XMLSchema#string

P2860

Small molecule inhibition of the KRAS-PDEδ interaction impairs oncogenic KRAS signalling

Normal and oncogenic p21ras proteins bind to the amino-terminal regulatory domain of c-Raf-1

Ras/Rap effector specificity determined by charge reversal

The Ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants

The 2.2 A crystal structure of the Ras-binding domain of the serine/threonine kinase c-Raf1 in complex with Rap1A and a GTP analogue

COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer

Increased frequency of the k-ras G12C mutation in MYH polyposis colorectal adenomas

Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

Discovery of Potent and Selective Covalent Inhibitors of JNK

Molecular switch for signal transduction: structural differences between active and inactive forms of protooncogenic ras proteins

P304

199-204

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/ANIE.201307387

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

53

http://www.w3.org/2001/XMLSchema#string

P50

Matthew Meyerson

P577

2013-11-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

258825191

http://www.w3.org/2001/XMLSchema#string

P698

24259466

http://www.w3.org/2001/XMLSchema#string

P932

3914205

http://www.w3.org/2001/XMLSchema#string